SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: quidditch who wrote (10591)2/24/2004 12:13:59 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
<MSHL, NVGN>

quid,

No idea - there's been no change in the fundamentals that I have seen. But there's been weakness in a lot of cancer-oriented stocks the last week or so. The only overall negatives I know of are the FDA commissioner and mutterings about Medicare not wanting to pay for off-label uses of expensive drugs.

I have a small position in both stocks - I might add if the weakness continues. Phenoxodiol is still very early of course.

Peter